Tiwari Neeraj, Garbi Natalio, Reinheckel Thomas, Moldenhauer Gerhard, Hämmerling Günter J, Momburg Frank
Department of Molecular Immunology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
J Immunol. 2007 Jun 15;178(12):7932-42. doi: 10.4049/jimmunol.178.12.7932.
MHC class I molecules present peptides derived from the ectodomains of endogenous transmembrane proteins; however, the processing of these Ags is incompletely understood. As model transmembrane Ags we investigated the processing of MHC-I-derived fusion proteins containing the N-terminally extended K(b)-restricted OVA epitope SIINFEKL in the extracytoplasmic domain. In TAP-deficient, nonprofessional APCs, the epitope was cleaved out of various sequence contexts and presented to T cells. Ag presentation was inhibited by acidophilic amines and inhibitors of the vacuolar proton pump, indicating processing in endosomes. Endosomal aspartic-type cathepsins, and to some extent also the trans-Golgi network protease furin, were involved in processing. Clathrin-dependent and independent internalization from the cell surface targeted MHC-I fusion proteins to early and late endosomes, where SIINFEKL/K(b) complexes were detected by immunofluorescence microscopy. Targeting of MHC-I fusion proteins to processing compartments was independent of sequence motifs in the cytoplasmic tail. Not only TAP-deficient cells, but also TAP-competent APCs used the vacuolar pathway for processing of MHC-I fusion proteins. Thus, endosomal processing of internalized endogenous transmembrane proteins represents a novel alternate pathway for the generation of MHC-I-binding peptides.
MHC I类分子呈递源自内源性跨膜蛋白胞外域的肽段;然而,这些抗原的加工过程尚未完全明确。作为模型跨膜抗原,我们研究了在胞外域含有N端延伸的K(b)限制性OVA表位SIINFEKL的MHC-I衍生融合蛋白的加工过程。在TAP缺陷的非专职抗原呈递细胞中,该表位从各种序列背景中被切割出来并呈递给T细胞。嗜酸性胺和液泡质子泵抑制剂可抑制抗原呈递,表明在内体中进行加工。内体天冬氨酸型组织蛋白酶以及在一定程度上反式高尔基体网络蛋白酶弗林蛋白酶参与了加工过程。网格蛋白依赖性和非依赖性的从细胞表面内化将MHC-I融合蛋白靶向早期和晚期内体,通过免疫荧光显微镜在其中检测到SIINFEKL/K(b)复合物。将MHC-I融合蛋白靶向加工区室与胞质尾中的序列基序无关。不仅TAP缺陷细胞,而且TAP功能正常的抗原呈递细胞都利用液泡途径加工MHC-I融合蛋白。因此,内化的内源性跨膜蛋白的内体加工代表了产生MHC-I结合肽的一种新的替代途径。